Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00564395 · ClinicalTrials.gov registry record · Phase 4
Detemir: Role in Type 1 Diabetes
A Phase 4 study of Type 1 Diabetes Mellitus, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT00564395 is a Phase 4 study of Type 1 Diabetes Mellitus that has completed, run by Montefiore Medical Center. The registered enrollment target is 18 participants, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00564395, a Phase 4 study of Type 1 Diabetes Mellitus, has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
Study of blood sugars in the children with Type 1 Diabetes Mellitus (T1DM), who are given insulin detemir and a rapid acting insulin (aspart). It is hypothesized that there is no difference in the patterns of blood sugars when detemir is given in the same syringe or in separate syringes with rapid acting insulin.
Conditions Studied
Interventions
- DRUG Insulin Detemir mixed with RAI injection
- DRUG Insulin Detemir and RAI injection
Study Locations (1)
Texas
- Texas Children's Hospital Endocrine and Diabetes Clinic - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2007-08 |
| Est. Completion | 2010-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00564395
The ClinicalTrials.gov registry entry for NCT00564395 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 140-participant average among 105 other Type 1 Diabetes Mellitus trials with a reported enrollment target (87% lower). The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 1 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Insulin Detemir mixed with RAI injection is the first listed.
NCT00564395 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00564395 about?
NCT00564395 is a clinical study titled "Detemir: Role in Type 1 Diabetes". Study of blood sugars in the children with Type 1 Diabetes Mellitus (T1DM), who are given insulin detemir and a rapid acting insulin (aspart). It is hypothesized that there is no difference in the patterns of blood sugars when detemir is given in the same syringe or in separate syringes with rapid a...
What is the current status of trial NCT00564395?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 18 participants. The study started on 2007-08. Estimated completion is 2010-05.
What conditions does trial NCT00564395 study?
This clinical trial studies the following conditions: Type 1 Diabetes Mellitus.
What interventions are being tested in trial NCT00564395?
The interventions under investigation include: Insulin Detemir mixed with RAI injection (DRUG), Insulin Detemir and RAI injection (DRUG).
Who is sponsoring clinical trial NCT00564395?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00564395 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dapagliflozin Plus Pioglitazone in T1DM
RECRUITING · Phase 4
-
CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)
COMPLETED · Phase 4
-
Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of Glucagon
COMPLETED · Phase 4
-
The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children
COMPLETED · Phase 4
-
Evaluate Use of Tropocells(R) Autologous Platelet-rich Fibrin (PRF) for Wagner Grade 1 and Grade 2, Mild to Mod Neuroischemic Plantar Diabetic Foot Ulcer Wound Care.
RECRUITING · Phase 2
-
Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.